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Venous thromboembolism (VTE), including pulmonary
embolism (PE) and deep venous thrombosis (DVT), is a
common and severe complication of critical illness.
Although well documented in the general population,
the prevalence of PE is less known in the ICU, where it is
more difficult to diagnose and to treat. Critically ill
patients are at high risk of VTE because they combine
both general risk factors together with specific ICU risk
factors of VTE, like sedation, immobilization, vasopressors
or central venous catheter. Compression ultrasonography
and computed tomography (CT) scan are the primary
tools to diagnose DVT and PE, respectively, in the ICU. CT
scan, as well as transesophageal echography, are good
for evaluating the severity of PE. Thromboprophylaxis is
needed in all ICU patients, mainly with low molecular
weight heparin, such as fragmine, which can be used
even in cases of non-severe renal failure. Mechanical
thromboprophylaxis has to be used if anticoagulation
is not possible. Nevertheless, VTE can occur despite
well-conducted thromboprophylaxis.Introduction
A 77-year-old man was admitted to the ICU as a result
of status epilepticus. He was mechanically ventilated for
3 days, and received 5,000 UI unfractionated heparin
(UFH) daily as thromboprophylaxis. The day after his
extubation, he became hypoxemic without hypotension.
A contrast enhanced computed tomography (CT) scan
of the chest (Fig. 1) showed a proximal bilateral pulmon-
ary embolism from the lobar to subsegmental arteries of
both sides. Transthoracic echocardiography and CT scan
did not show any signs suggestive of right ventricular* Correspondence: CMinet@chu-grenoble.fr
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unless otherwise stated.strain. He recovered with a therapeutic dose of heparin,
and was discharged home 1 week later. This clinical case
shows that clinical presentation of proximal pulmonary
embolism is not typical in mechanical ventilated patients
and can occur under thromboprophylaxis.
Venous thromboembolism (VTE), including deep ven-
ous thrombosis (DVT) and pulmonary embolism (PE), is
a common complication in the ICU. Critically ill patients
are at high risk of VTE as they are susceptible to both
general risks factors of VTE as well as those specific to
ICU patients, such as sedation, immobilization, and va-
sopressors. The prevalence of VTE, and especially of PE,
is underestimated in the ICU, as it is often clinically si-
lent, especially in sedated and mechanically ventilated
patients. ICU-acquired thromboembolic events are diffi-
cult to diagnose, as they may mimic many other
diseases.
Our purpose was to conduct a review of the most rele-
vant published clinical studies on ICU-acquired VTE in
order to highlight the main characteristics and the
current strategies for the diagnosis and prevention of
this disease.Search strategy
A search on the PubMed database for English language
publications between 1981 and 2014 was performed
using search terms “VTE in ICU”, “risk factors of VTE
in ICU”, “thromboprophylaxis in ICU”, “pulmonary em-
bolism in ICU”, “deep venous thrombosis in ICU”,
“mechanical thromboprophylaxis”, “diagnosis of pul-
monary embolism in ICU”.Epidemiology
PE is one of the three most frequently underdiagnosed
illnesses identified during autopsies [1]. Autopsy studies
detected PE in 7 to 27 % of critically ill patients; of these,
only one-third were clinically suspected [2].
When PE is clinically suspected, there are three categor-
ies of risk: high-risk patients, who are hemodynamicallys distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Fig. 1 Proximal bilateral pulmonary embolism on computed
tomography scan in a mechanically ventilated ICU patient
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high-risk patients, who are normotensive with a Pulmon-
ary Embolism Severity Index (PESI) ≥ III or a simplified
(s)PESI ≥1 and in whom there is right ventricular failure
or a rise of cardiac biomarkers; and low risk patients, who
have a PESI of class I or II, or a sPESI of 0 [3]. Studies on
VTE in the ICU predominantly focus on DVT. The inci-
dence of DVT ranges from 5 to 31 % according to the
case-mix and the diagnosis methods used [4–10] (Tables 1
and 2).
In a medical-surgical ICU, when compression ultra-
sonography (CUS) was performed, the incidence of DVT
ranged from 10 to 100 % in patients with no clinical sus-
picion of DVT [11, 12]. Among patients with trauma,
routine CT scans discovered asymptomatic PE in 24 %
of patients [13].
The prevalence and incidence of PE in the ICU remain
unclear. Three recent prospective studies have investi-
gated the incidence of PE in the ICU. A PE was clinically
suspected in 0.4 to 2.3 % of medical ICU patients [14, 15];
the incidence rose to 3.2 % in post-traumatic ICU pa-
tients [16], although most patients had thromboprophy-
laxis. In the PROTECT trial comparing prophylaxis
with dalteparin versus UFH in critically ill patientsTable 1 Rate of deep venous thrombosis in critically ill patients with
trials versus groups with thromboprophylaxis)
Study Study design Population
Moser et al. 1981 [4] Prospective cohort Respiratory ICU
Cade 1982 [5] Blinded RCT General ICU patients
Kapoor et al. 1999 [6] Blinded RCT Medical ICU patients
Fraisse et al. 2000 [7] Blinded RCT Exacerbated COPD patients with
mechanical ventilation >48 hou
COPD chronic obstructive pulmonary disease; CUS compression ultrasonography; DV(90 % mechanically ventilated), a clinically suspected
PE was diagnosed in 1.3 % and 2.3 % of patients, re-
spectively [8].
In 176 consecutive mechanically ventilated patients re-
quiring a CT scan for any medical reason, we applied a
standard imaging protocol to detect PE [17]. PE was di-
agnosed in 33 (18.7 %) patients, and was clinically silent
in 20 (60 %) of these [17]. CUS was performed within
48 hours of the CT scan and detected DVT associated
with PE in 11 (33 %) patients. Thirty-five (19.9 %) of the
176 patients had a diagnosis of DVT, despite pharmaco-
logical thromboprophylaxis or anticoagulant treatment
administered to 92 (52.2 %) of them.
PE is associated with a high mortality rate, especially
when it is associated with right ventricular failure or
shock [18]. Mortality in untreated PE is approximately
30 %, but with adequate (anticoagulant) treatment, this
can be reduced to 2 to 8 % [19].
Diagnosis of ICU-acquired venous
thromboembolism
DVT can be ruled out in an outpatient who is judged
clinically unlikely to have it and who has a negative D-
dimer test [20]. But D-dimer levels can rise in some
pathologies like atrial fibrillation, acute coronary syn-
dromes, stroke, acute upper gastrointestinal hemorrhage,
infection, disseminated intravascular coagulation, and se-
vere renal dysfunction, which are frequent in critically ill
patients. As such, D-dimer levels have low specificity in
the ICU [21]. Crowther et al. [22] have shown that nei-
ther hypercoagulability nor D-dimer levels predict critic-
ally ill patients at risk of DVT and should thus not be
used as a diagnostic test for it.
In the general population, CUS is now the first choice
to diagnose DVT with high sensitivity and specificity
[23]. Outpatients with symptoms of DVT and two con-
secutively negative CUS exams within 7 days have less
than 1 % risk to develop DVT, suggesting that CUS is
accurate for ruling out clinically important DVT [24].
DVT can be excluded based on a negative single prox-
imal CUS in patients with low and intermediate clinical
probability of DVT [25]. In critically ill patients, anout thromboprophylaxis (control groups in randomized clinical
DVT screening method Number of patients DVT (%)
I-labeled fibrinogen leg scanning
for 3-6 days
23 13
125I-labeled fibrinogen leg scanning
for 4-10 days
59 29
CUS at admission and every 3 days 390 31
rs
CUS (weekly) and venography
(before day 21)
85 28
T deep vein thrombosis; RCT randomized clinical trial
Table 2 Rates of deep vein thrombosis in critically ill patients with thromboprophylaxis
Author (Year) Study design Population DVT screening method Thromboprophylaxis Number
of patients
DVT (%)
Ibrahim et al. 2002 [10] Prospective study Medical ICU patients;
MV >7 days
Serial CUS (weekly) Twice daily SC UFH
5,000 UI
110 23.6
Cook et al. 2005 [9] Prospective study Medical-surgical ICU CUS 48 hours after admission,
twice weekly and in case of clinical
suspicion
Twice daily SC UFH
5,000 UI
261 9.6
PROTECT 2011 [8] Blinded RCT Medical-surgical ICU CUS 48 hours after admission,
twice weekly and in case of clinical
suspicion




CUS compression ultrasonography; DVT deep vein thrombosis; MV mechanical ventilation; RCT randomized clinical trial; SC subcutaneous; UFH unfractionated
heparin
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be achieved by intensivists performing lower limb CUS
at the bedside, with a sensitivity of 85 % and a specificity
of 96 % [26].
A chest CT-based approach has now replaced the gold
standard pulmonary angiography with equivalent clinical
validity to rule out PE [27]. CT pulmonary angiography
(CTPA) has become the imaging reference exam to diag-
nose PE in the ICU. Multi-detector CT angiography at
1.25 mm collimation thickness is the most sensitive and
allows better imaging of segmental and sub-segmental
pulmonary arteries [28]. In cases where PE is suspected,
multi-detector CT angiography sensitivity ranged be-
tween 83 and 100 %, and its specificity ranged between
89 and 97 % [29], although this study did not provide
specific data for the ICU population. CT scans can also
be useful for determining the severity of acute pulmon-
ary embolisms, by evaluating right ventricular dysfunc-
tion, which is well correlated with echocardiography
findings [30, 31].
As CTPA requires patients to be transported to the
radiology department and in a rather stable state, it can-
not be performed in all ICU patients with a clinical sus-
picion of PE. Moreover, intra-hospital transport may
have a negative impact on ventilated critically ill patients
[32]. This explains the delayed use of such definitive
diagnostic tests in the ICU. Most epidemiologic studies
have to be interpreted with caution, as the diagnosis of
PE is often based on questionable definitions. We identi-
fied only two prospective studies evaluating the rate of
PE in critically ill patients with a standardized protocol
of CT scans performed in a homogenous consecutive
population: one in severe injured trauma patients (24 %
PE when scanning asymptomatic severe injured patients)
[13]; and one in mechanically ventilated patients (18.7 %
PE using a standard imaging protocol to detect PE dur-
ing CT scan for any other medical reason) [17].
Transthoracic echocardiography (TTE) could be help-
ful in the diagnosis of PE at the bedside by looking for
right ventricular hypokinesis, increases in right ventricu-
lar end-diastolic diameter, or tricuspid regurgitationvelocity. Miniati et al. [33] showed that TTE could help
to assess the physiological effects of PE but that it fails
to identify more than 50 % of PE proven on pulmonary
angiography. TTE requires better sensitivity for it to be
used as a screening test to rule out PE.
Transesophageal echocardiography (TEE) could be
useful in PE diagnosis, particularly in hemodynamically
unstable patients who have predominantly bilateral cen-
tral PE. This exam is non-invasive, can be done at the
bedside, identifies clots and, compared with CT scan-
ning, has very good sensitivity and specificity (80 % and
100 %, respectively, in Pruszczyk et al.’s study [34]). But
TEE has a higher failure rate than CT scans for diagnosis
of distal PE.
Venous thromboembolism risk factors more
specific to critically ill patients
ICU patients share similar general risk factors for VTE
with other patients: age, immobilization, obesity, past
history of personal or familial VTE, past history of neo-
plasm, sepsis, stroke, respiratory or heart failure, preg-
nancy, trauma, or recent surgery [9, 17, 35–37].
Additional, specific risk factors for the ICU population
have also been described [35, 38] (Table 3).
Mechanical ventilation, by decreasing venous return
and requiring sedation (and immobilization) increases
the risk of VTE. Although critically ill patients with
DVT had a longer duration of mechanical ventilation
than those who did not [9], the causal relationship be-
tween length of mechanical ventilation and VTE is un-
clear [17]. Sedation is not an independent risk factor in
itself.
Central venous catheterization is another important
risk factor for ICU-acquired VTE [39], especially when
inserted in femoral veins [38, 40], with a catheter-related
thrombosis occurrence rate ranging from 2.2 % [8] up to
69 % [17]. Catheter-related thrombosis was originally de-
scribed by Chastre et al. [41]. The incidence of throm-
bosis is 2 to 10 % with subclavian catheter [39, 40] but
may reach 10 to 69 % with femoral catheter [17, 40, 42,
43] and 40 to 56 % with internal jugular catheter. In
Table 3 Venous thromboembolism risk factors
General VTE risk factors ICU-acquired VTE risk factor
Age Sepsis
Past history of VTE Vasopressor use
Past history of cancer Respiratory or cardiac failure
Immobilization Pharmacologic sedation
Obesity Mechanical ventilation
Pregnancy Central venous catheter
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of associated PE is 7 to 17 % [44, 45]. Lower-limb DVT
was associated with a four-fold increase in the risk of PE
[17], whereas upper-limb DVT was not a significant risk
factor for PE [46–48]. Catheter-related thrombosis risk
increases with the duration of catheter placement [10].
In the ICU, catheter-related thrombosis is more frequent
in older patients, with femoral catheters, when catheters
are inserted in an emergency situation, and in patients
not receiving therapeutic heparin [39, 40]. Sepsis may in-
duce procoagulant status and favor catheter-related
thrombosis. Catheter-related sepsis is often associated
with catheter-related thrombosis [49], and also in ICU
patients [39].
Vasopressor administration was found to be an inde-
pendent risk factor for DVT (hazard ratio 2.8, 95 % confi-
dence interval 1.1 to 7.2) [9], certainly explained by
reduced absorption of subcutaneous heparin linked to the
vasoconstriction of peripheral blood vessels. This mechan-
ism could explain the lower anti-Xa factor activity after
thromboprophylaxis with low molecular weight heparin
(LMWH) in critically ill patients on vasopressors [50].
Platelet transfusion (hazard ratio 3.2, 95 % confidence
interval 1.2 to 8.4) [9] and high levels of platelets (odds
ratio 1.003, 95 % confidence interval 1.000 to 1.006)
[17] have been identified as risk factors for VTE,
certainly related to increased platelet activation and ad-
herence to vessel walls with subsequent fibrin clot for-
mation, as described in inflammatory processes and
sepsis [51].
The level of risk of VTE in critically ill patients also
depends on the underlying illness leading to ICU ad-
mission [52].
Is there a rationale to use thromboprophylaxis in
critically ill patients?
Thromboprophylaxis is recommended in the general
surgical [53] and medical [54] populations. In the ICU,three randomized controlled trials (RCTs), comparing
thromboprophylaxis with placebo using objective screen-
ing for DVT [5–7] (Table 4), found that the rate of DVT
was significantly lower in the thromboprophylaxis group
regardless of the thromboprophylaxis used, UFH [5, 6]
or LMWH [7]. The American College of Chest Physi-
cians (ACCP) recommends thromboprophylaxis for
prevention of VTE in critical care patients (grade Ia:
strong recommendation with high quality of evidence)
[35, 55]. Moreover, omission of thromboprophylaxis
within the first 24 hours of ICU admission without ob-
vious reasons is associated with a higher risk of mortal-
ity in the ICU [56].
In the ICU, up to 80 % of patients under thrombopro-
phylaxis have at least one episode of bleeding, more
often minor [57]. Major bleeding is described in 5.6 % of
critically ill patients with or without preventive anticoa-
gulation [57], and up to 7.2 % when dalteparin is used in
severe renal insufficiency patients [58].Which thromboprophylaxis for which patients in
the ICU?
Unfractionated heparin versus low molecular weight
heparin
In general surgical patients [59] and medically ill in-
patients [60], LMWH and UFH have similar efficacy
and safety. In patients with major trauma, enoxaparin
(LMWH) was more effective than subcutaneous UFH
[61]. In patients with heart failure or severe respiratory
disease, enoxaparin 40 mg once daily was as effective as
5,000 UI UFH three times daily for prevention of
thromboembolic events [62].
Until now, the PROTECT study [8] is the only RCT to
have compared UFH with LMWH as VTE prophylaxis
in the ICU, excluding patients at very high risk of bleed-
ing. Overall, 3,764 patients, including 90 % mechanically
ventilated patients, were randomly allocated to receive
5,000 UI subcutaneous dalteparin once daily plus pla-
cebo once daily, or 5,000 UI subcutaneous UFH twice
daily. DVT was screened for using CUS within 48 hours
after admission, and then twice weekly or in case of clin-
ical suspicion. There was no significant difference in
proximal DVT: 5.1 % DVT in the dalteparin group ver-
sus 5.8 % in the UFH group (P = 0.57). However, the rate
of PE was significantly lower in the dalteparin group
(1.3 %) compared with the UFH group (2.3 %) (P = 0.01).
A recent review described a significant reduction in
PE, but not DVT, with LMWH compared with UFH,
with a similar rate of bleeding [63]. ACCP recommends
the use of LMWH or UFH thromboprophylaxis in crit-
ical care patients at moderate risk for VTE and LMWH
for critical care patients at higher risk (major trauma or
orthopedic surgery patients) (grade Ia) [35, 55].
Table 4 Thromboprophylaxis in ICU (blinded randomized controlled trials)
DVT (%) PE (%)
Author (Year) Population Number of
patients
Diagnosis method Control Intervention Control Intervention P-value Control Intervention P-value






Placebo UFH 5,000 UI SC
twice daily
NR/NR (29 %) NR/NR (13 %) <0.05
Kapoor et al. 1999 [6] Medical ICU
patients
791 CUS at admission and
every 3 days
Placebo UFH 5,000 UI SC
twice daily
122/390 (31 %) 44/401 (11 %) 0.001
Fraisse et al. 2000 [7] Exacerbated COPD
patients with MV
>48 hours







24/85 (28 %) 13/84 (15.5 %) <0.045
PROTECT 2011 [8] Medico-surgical
ICU patients
3764 CUS at admission,







UI SC once daily
plus placebo
96/1,873 (5.1 %) 109/1,873 (5.8 %) 0.57 43/1,873 (2.3 %) 24/1,873 (1.3 %) 0.01
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critically ill patients?
Anti-factor Xa level is a clinically practicable marker of
LWMH anticoagulant effectiveness; levels of 0.1 to 0.3
UI/ml are considered as effective antithrombotic activity.
There is no need to systematically measure anti-factor
Xa levels for each patient but it could be useful in some
populations such as critically ill patients because possible
patient-dependent factors can influence plasma anti-
factor Xa activity, like decreased bioavailability because
of edema, vasoconstrictive treatment or renal failure.
Lower anti-factor Xa levels in blood have been reported
in ICU patients with generalized edema [64] or receiving
vasopressors [50, 65]. This can be explained by impaired
peripheral circulation. The systemic bioavailability of the
anticoagulant may then be inadequate. However, Priglinger
et al. [65] did not show any correlation between dose of
norepinephrine and anti-factor Xa blood levels. Robinson
et al. [66] conducted a RCT showing that an increase in
enoxaparin dose led to significantly increased anti-factor
Xa activity but a ceiling effect seems to exist at the dose of
60 mg/day [66]. Mayr et al. also reported an anti-factor Xa
activity below the recommended level (0.1 to 0.3 UI/ml) in
ICU patients; it was significantly correlated to multiple
organ dysfunction as well as to a high body weight [67].
These results suggest that an inadequate dose of enox-
aparin can fail to prevent VTE in critically ill patients.
Its efficacy should be controlled by monitoring the anti-
factor Xa activity in each ICU patient, regardless of the
patient’s renal function.
Low molecular weight heparins and renal insufficiency in
critically ill patients
LMWHs are more dependent on renal clearance than
UFHs and could bioaccumulate in patients with renal in-
sufficiency, causing more bleeding. Critically ill patients
are at higher risk of acute renal failure; at ICU admission,
nearly one-third of patients have a creatinine clearance
below 30 ml/minute [9]. This reduced renal clearance ofTable 5 Randomized clinical trials evaluating mechanical thrombop









Elliott et al. 1999 [74] Trauma patients 149 CUS
Ginzburg et al. 2003 [75] Trauma patients 442 CUS
adm
Kurtoglu et al. 2004 [73] Trauma patients 120 CUS
1 w
CUS compression ultrasonography; DVT deep vein thrombosis; GCS graduated comp
molecular weight heparinLMWH has led to recommendations to monitor LMWH
blood levels in patients with severe renal insufficiency
[68]. A first meta-analysis failed to demonstrate bio-
accumulation of LMWH used as thromboprophylaxis in
critically ill patients with renal insufficiency [69]. Two re-
cent prospective observational studies have been per-
formed: the first is a single-center cohort study enrolling
19 patients with a creatinine clearance of 30 ml/minute or
above at ICU admission, receiving 5,000 UI subcutaneous
dalteparin daily [70]. The second study was a multicen-
ter prospective cohort study of 138 ICU patients with
an estimated creatinine clearance under 30 ml/minute
[58], and who received 5,000 UI subcutaneous dalte-
parin once daily for thromboprophylaxis. No bio-
accumulation of LMWH occurred in both studies.
Dalteparin has not been associated with bleeding in
critically ill patients with severe renal insufficiency.
However, the impact of LMWHs other than dalteparin
is still controversial.
Mechanical thromboprophylaxis in ICU patients
When anticoagulant is contraindicated, mechanical
thromboprophylaxis using either graduated compression
stockings (GCS) or intermittent pneumatic compression
(IPC) may be proposed. Thromboprophylaxis by mech-
anical means alone is recommended for critical care pa-
tients at high risk of bleeding with contraindications to
prophylaxis with anticoagulant agents [35]. The main
RCTs that include GCS or IPC for DVT prophylaxis in
ICU patients are listed in Table 5 [71]; one was con-
ducted in patients with acute myocardial infarction [72],
and three others in trauma patients [73–75]. These four
studies represent 791 patients who underwent mechan-
ical prophylaxis (several methods were evaluated) or re-
ceived LMWH. One study evaluated GCS on one leg
versus nothing on the second leg in each patient; the in-
cidence of DVT was lower with GCS (0 % versus 10 %)
[72]. Combining IPC with GCS was not more effective
than GCS alone [76]. In neurosurgical patients, GCSrophylaxis in the ICU





No GCS 8 (10 %) 0.003
GCS 0 (0 %)
on day 8 or before Calf-thigh IPC 4 (6.5 %) 0.009
Plantar venous IPC 13 (21 %)
within 24 hours of
ission and weekly
IPC 6 (2.7 %) 0.12
LMWH 1 (0.5 %)
on admission, weekly, and
eek after discharge
IPC 4 (6.6 %) 0.04
LMWH 3 (5 %)
ression stockings; IPC intermittent pneumatic compression; LMWH low
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bined with LMWH [77].
The use of vena cava filters for thromboprophylaxis is
not recommended by the ACCP Evidence-Based Clinical
Practice Guidelines (eighth edition) [35].
Thromboprophylaxis compliance in the ICU
The ENDORSE multinational study enrolled 68,183 hos-
pitalized patients in an acute care setting and showed
that only a low rate of patients had appropriate prophy-
laxis according to the 2004 ACCP guidelines on VTE
prophylaxis. In an Asian ICU, a recent observational
study revealed that 20 % of the critically ill patients did
not receive the appropriate recommended prophylaxis
[78]. In North-American ICUs, Lauzier et al. [79] re-
cently reported appropriate guideline concordance oc-
curred for 95.5 % patient-days, which was better in
sicker patients and in patients with a previous history of
VTE or cancer. LMWH was less used than UHF in
sicker and surgical patients, and in patients receiving va-
sopressors or renal replacement therapy [79].
What about asymptomatic pulmonary embolism?
The prevalence of incidental emboli in in-patients varies
from 0.6 to 5.7 % [80]. In moderate to severe injured
trauma patients, CT scans showed asymptomatic PE in
22 (24 %) patients, of which 30 % were receiving throm-
boprophylaxis. Only four patients with a major clot, and
one with a minor clot but with an associated DVT, were
treated at therapeutic doses. None of the 10 patients
with minor clot and no therapeutic anticoagulation ther-
apy was associated with any complication attributable to
thromboembolic disease within 3 months [13]. In our
study of mechanically ventilated patients in the ICU, 33
of 176 (18.7 %) patients had a diagnosed PE; 20 of these
were asymptomatic (60 %) [17]. All these patients were
treated early with therapeutic anticoagulation whenever
they had lobar, segmental or subsegmental PE. ICU and
hospital mortality were not different between patients
with and without diagnosed PE.
So what should we do for asymptomatic PE cases?
Should we routinely look to detect all asymptomatic PE?
Although it seems evident to treat all PE, regardless of
their symptoms, once they are detected, should we treat
all asymptomatic PE cases? Most unsuspected emboli
found on CT scans are small and segmental or subseg-
mental [81] and their management is not clear. Patients
with false negative undiagnosed PE on CT scan have fa-
vorable short-term outcome without therapeutic antic-
oagulation [82]. Eyer et al. [83] also demonstrated no
attributable mortality with untreated subsegmental emboli.
On the other hand, early diagnosis of PE and routine use
of early therapeutic anticoagulation in symptomatic or
asymptomatic PE contributed to a low rate of fatal PE [17].These results seem to support the need for routinely look-
ing for PE in patients receiving mechanical ventilation.
Whether mortality would be higher if these asymptomatic
PE cases are not treated remains to be evaluated.
Conclusion
Diagnosis and management of clinically silent PE in critic-
ally ill patients are challenging. Current diagnosis tools,
such as CTPA, allow the efficient diagnosis of silent PE if
carried out systematically in mechanically ventilated pa-
tients. Considering the high risk of VTE in ICU patients,
including specific VTE risk factors like mechanical ventila-
tion, vasopressor use and central venous catheter use,
thromboprophylaxis is recommended. LMWH could be
more effective than UFH for VTE prophylaxis in the ICU.
However, the high risk of bleeding in many critically ill pa-
tients makes the benefit-risk ratio of thromboprophylaxis
difficult to evaluate. Further research on the diagnosis of
PE and on whether asymptomatic peripheral PE should be
treated or not is needed.
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